Fanapt for a $25 billion market was FDA approved a few weeks ago.
It has been shown to be efficacious as Risperdal which had $5 billion of sales.
TTNP's royalty on $5 billion of sales would be $496 million or earnings or $8.50 per share.
Even if Fanapt is a complete bust and only sells $1 billion, comparable to the smallest selling psychosis drug, Geodon, royalties would still be $96 million or $1.80 per share.
TTNP is currently $1.06 with a market cap of only $70M.
TTNP also has Probuphine with a successful Phase 3 using it's ProNeura slow release technology for opiod addiction and a Phase 2 for chronic pain.
TTNP is the most undervalued biotech out there.